BE897280A - Perfectionnements a des compositions d'alcaloides de vinca - Google Patents
Perfectionnements a des compositions d'alcaloides de vinca Download PDFInfo
- Publication number
- BE897280A BE897280A BE0/211170A BE211170A BE897280A BE 897280 A BE897280 A BE 897280A BE 0/211170 A BE0/211170 A BE 0/211170A BE 211170 A BE211170 A BE 211170A BE 897280 A BE897280 A BE 897280A
- Authority
- BE
- Belgium
- Prior art keywords
- solution
- composition according
- approximately
- vincristine
- mannitol
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 229940122803 Vinca alkaloid Drugs 0.000 title claims description 9
- 239000000243 solution Substances 0.000 claims abstract description 55
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical group C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims abstract description 22
- 229960004528 vincristine Drugs 0.000 claims abstract description 20
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims abstract description 20
- 241000863480 Vinca Species 0.000 claims abstract description 16
- 239000000539 dimer Substances 0.000 claims abstract description 16
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims abstract description 14
- 239000003755 preservative agent Substances 0.000 claims abstract description 13
- 229920005862 polyol Polymers 0.000 claims abstract description 11
- 150000003077 polyols Chemical class 0.000 claims abstract description 11
- 230000002335 preservative effect Effects 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 239000008351 acetate buffer Substances 0.000 claims abstract description 8
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims abstract description 7
- 229960003048 vinblastine Drugs 0.000 claims abstract description 6
- 235000000346 sugar Nutrition 0.000 claims abstract description 5
- GLDSBTCHEGZWCV-HLTPFJCJSA-N leuroformine Chemical compound C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C=O)=C2C=C1OC GLDSBTCHEGZWCV-HLTPFJCJSA-N 0.000 claims abstract description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical group COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 24
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 24
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 13
- 229930195725 Mannitol Natural products 0.000 claims description 13
- 239000000594 mannitol Substances 0.000 claims description 13
- 235000010355 mannitol Nutrition 0.000 claims description 13
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 12
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 12
- 229960002216 methylparaben Drugs 0.000 claims description 12
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 12
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 12
- 229960003415 propylparaben Drugs 0.000 claims description 12
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 claims description 12
- 229960002110 vincristine sulfate Drugs 0.000 claims description 12
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 7
- KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 claims description 7
- 229960004982 vinblastine sulfate Drugs 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 claims description 4
- KABRXLINDSPGDF-UHFFFAOYSA-N 7-bromoisoquinoline Chemical compound C1=CN=CC2=CC(Br)=CC=C21 KABRXLINDSPGDF-UHFFFAOYSA-N 0.000 claims description 4
- 229960004355 vindesine Drugs 0.000 claims description 4
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims description 4
- 229960005212 vindesine sulfate Drugs 0.000 claims description 4
- 231100000167 toxic agent Toxicity 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000000174 oncolytic effect Effects 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 229930013930 alkaloid Natural products 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- -1 amide derivative of vinblastine Chemical class 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 150000003797 alkaloid derivatives Chemical group 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- UKTNDLHXQNQKBH-UHFFFAOYSA-N 2,3-dihydro-1h-indole;1h-indole Chemical class C1=CC=C2NCCC2=C1.C1=CC=C2NC=CC2=C1 UKTNDLHXQNQKBH-UHFFFAOYSA-N 0.000 description 1
- 208000032529 Accidental overdose Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 240000001829 Catharanthus roseus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229940124675 anti-cancer drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39965482A | 1982-07-19 | 1982-07-19 | |
| US47607783A | 1983-03-17 | 1983-03-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE897280A true BE897280A (fr) | 1984-01-13 |
Family
ID=27016716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE0/211170A BE897280A (fr) | 1982-07-19 | 1983-07-13 | Perfectionnements a des compositions d'alcaloides de vinca |
Country Status (16)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3536745A1 (de) * | 1984-10-16 | 1986-04-17 | Richter Gedeon Vegyeszet | Metallkomplexe der bis-indolverbindungen und diese enthaltende arzneimittelpraeparate |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2597750B1 (fr) * | 1986-04-25 | 1989-06-02 | Pf Medicament | Solution aqueuse stable de sulfate de vincristine |
| FR2623089B1 (fr) * | 1987-11-13 | 1990-04-27 | Pf Medicament | Composition pharmaceutique pour l'administration parenterale de navelbine |
| US4923876A (en) * | 1988-04-18 | 1990-05-08 | Cetus Corporation | Vinca alkaloid pharmaceutical compositions |
| HU204995B (en) * | 1989-11-07 | 1992-03-30 | Richter Gedeon Vegyeszet | Process for producing pharmaceutical composition comprising alkaloid with bis-indole skeleton, with antitumour activity and suitable fr parenteral purposes |
| FR2910812B1 (fr) * | 2006-12-29 | 2009-03-20 | Pierre Fabre Medicament Sa | Compositions pharmaceutiques injectables lyophilisees de derives hemi-synthetiques d'alcaloide de vinca stables a temperature ambiante |
| US11058679B2 (en) | 2015-08-01 | 2021-07-13 | Sun Pharmaceutical Industries Ltd. | Dosage form of vinca alkaloid drug |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3097137A (en) * | 1960-05-19 | 1963-07-09 | Canadian Patents Dev | Vincaleukoblastine |
| US3749784A (en) * | 1972-05-03 | 1973-07-31 | Lilly Co Eli | Psoriasis treatment |
| GB2020180B (en) * | 1978-05-08 | 1982-08-25 | Nelson Res & Dev | Ophthalmic compositions containingcolchicine or vinblastinr |
| US4208414A (en) * | 1978-06-05 | 1980-06-17 | Eli Lilly And Company | Vinblastine in rheumatoid arthritis |
| US4259242A (en) * | 1978-10-10 | 1981-03-31 | Eli Lilly And Company | Method of preparing vindesine sulfate |
| HU181940B (en) * | 1979-11-02 | 1983-11-28 | Richter Gedeon Vegyeszet | Process for producing solutions of vincane derivatives for parentheral application |
| OA06421A (fr) * | 1980-06-10 | 1981-09-30 | Omnium Chimique Sa | Procédé de préparation de dérivés N-(vinblastinoyl-23) d'acides aminés et de peptides. |
-
1983
- 1983-06-15 IT IT21644/83A patent/IT1170152B/it active
- 1983-07-11 DE DE19833324964 patent/DE3324964A1/de active Granted
- 1983-07-11 CH CH3808/83A patent/CH654744A5/de not_active IP Right Cessation
- 1983-07-12 NZ NZ204868A patent/NZ204868A/en unknown
- 1983-07-12 FR FR8311595A patent/FR2531860B1/fr not_active Expired
- 1983-07-12 IL IL69203A patent/IL69203A/xx not_active IP Right Cessation
- 1983-07-13 PH PH29226A patent/PH19098A/en unknown
- 1983-07-13 LU LU84910A patent/LU84910A1/fr unknown
- 1983-07-13 BE BE0/211170A patent/BE897280A/fr unknown
- 1983-07-15 IE IE1646/83A patent/IE55388B1/en not_active IP Right Cessation
- 1983-07-15 AU AU16891/83A patent/AU553514B2/en not_active Expired
- 1983-07-15 SE SE8304009A patent/SE463804B/sv not_active IP Right Cessation
- 1983-07-15 HU HU832522A patent/HU191538B/hu unknown
- 1983-07-15 NL NLAANVRAGE8302552,A patent/NL184146C/xx not_active IP Right Cessation
- 1983-07-15 GB GB08319146A patent/GB2125292B/en not_active Expired
-
1987
- 1987-05-28 HK HK430/87A patent/HK43087A/xx not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3536745A1 (de) * | 1984-10-16 | 1986-04-17 | Richter Gedeon Vegyeszet | Metallkomplexe der bis-indolverbindungen und diese enthaltende arzneimittelpraeparate |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2531860B1 (fr) | 1986-09-26 |
| IL69203A (en) | 1986-03-31 |
| FR2531860A1 (fr) | 1984-02-24 |
| NL184146B (nl) | 1988-12-01 |
| SE463804B (sv) | 1991-01-28 |
| NZ204868A (en) | 1986-10-08 |
| SE8304009D0 (sv) | 1983-07-15 |
| GB2125292B (en) | 1986-06-04 |
| IE831646L (en) | 1984-01-19 |
| NL184146C (nl) | 1989-05-01 |
| DE3324964C2 (enrdf_load_stackoverflow) | 1991-03-14 |
| LU84910A1 (fr) | 1985-04-17 |
| GB2125292A (en) | 1984-03-07 |
| HK43087A (en) | 1987-06-05 |
| GB8319146D0 (en) | 1983-08-17 |
| SE8304009L (sv) | 1984-01-20 |
| NL8302552A (nl) | 1984-02-16 |
| IE55388B1 (en) | 1990-08-29 |
| DE3324964A1 (de) | 1984-01-19 |
| IL69203A0 (en) | 1983-11-30 |
| IT8321644A0 (it) | 1983-06-15 |
| IT1170152B (it) | 1987-06-03 |
| CH654744A5 (de) | 1986-03-14 |
| HU191538B (en) | 1987-03-30 |
| AU553514B2 (en) | 1986-07-17 |
| AU1689183A (en) | 1984-01-26 |
| PH19098A (en) | 1986-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9265832B2 (en) | Stabilized pemetrexed formulation | |
| EP2995298B1 (en) | Stabilized pemetrexed preparation | |
| CH695185A5 (fr) | Compositions pharmaceutiques injectables contenant de la piperacilline et du tazobactame et procede pour leur production. | |
| OA10678A (fr) | Nouvelles formulations liquides stables à base de paracétamol et leur mode de préparation | |
| US6686365B2 (en) | Pharmaceutical composition | |
| WO2013144814A1 (en) | Stable ready-to-use pharmaceutical composition of pemetrexed | |
| EP1265612B1 (en) | Pharmaceutical composition comprising pemetrexed together with monothioglycerol, l-cystein or thioglycolic acid | |
| JP2020125359A (ja) | ペメトレキセドまたはその薬剤学的に許容可能な塩を含有する安定化された薬学組成物 | |
| BE897280A (fr) | Perfectionnements a des compositions d'alcaloides de vinca | |
| US4619935A (en) | Stable oncolytic formulations | |
| OA13348A (fr) | Composition pharmaceutique de vinflunine destinée à une administration parentérale, procédé de préparation et utilisation. | |
| US6048540A (en) | Acetamenophen composition with reduced liver toxicity | |
| IE71022B1 (en) | Stabilizer for 4-ethyl-2-hydroxyimino-5-nitro-3-hexenamides containing preparation and stabilizing method therefor | |
| CN113350271B (zh) | 一种质子泵抑制剂的组合物及其制备方法 | |
| EP4360622A1 (en) | Ketorolac liquid composition, preparation method therefor, and application thereof | |
| KR20250099117A (ko) | 도파민을 포함하는 약학적 주사용액 | |
| CA2677856A1 (en) | Pharmaceutical carrier composition and pharmaceutical composition | |
| JPS5929617A (ja) | ビンカ・アルカロイド製剤 | |
| JP2025511651A (ja) | ペメトレキセド二ナトリウム液体組成物、その製造方法及び応用 | |
| CN1174702A (zh) | 药物缓慢释放剂 | |
| HK40020412B (en) | A stable aqueous hydroxycarbamide solution | |
| HK40020412A (en) | A stable aqueous hydroxycarbamide solution | |
| HK1052461B (en) | Pharmaceutical composition comprising pemetrexed together with monothioglycerol, l-cystein or thioglycolic acid |